Status:
COMPLETED
Efficacy of Single Versus Double Dose of Oral Amoxicillin for Non-Severe Pneumonia in Children
Lead Sponsor:
ARI Research Cell
Collaborating Sponsors:
World Health Organization
Conditions:
Pneumonia
Eligibility:
All Genders
2-59 years
Phase:
PHASE1
PHASE2
Brief Summary
The World Health Organization's (WHO) standard case management strategy for reducing acute respiratory infection (ARI) related mortality recommends oral cotrimoxazole and oral amoxicillin as first lin...
Detailed Description
INTRODUCTION: World Health Organization's (WHO) standard case management strategy for reducing ARI related mortality recommends oral cotrimoxazole and oral amoxicillin as first line drugs for the tre...
Eligibility Criteria
Inclusion
- They are aged 2-59 months.
- Diagnosed with WHO defined non-severe pneumonia
Exclusion
- Children with signs of WHO defined severe or very severe disease.
- Known penicillin allergy, with a history of accelerated rash, urticaria, or anaphylactic symptoms. Complicating acute non-pulmonary or chronic illness.
- The children living outside the municipal limits of the city who cannot be followed up.
- Children who have taken the appropriate doses of WHO-recommended dose of antimicrobial drug for 48 hours prior to presentation.
- Children who have prior history of wheezing or bronchial asthma and are wheezing now.
- Children whose parents or guardians refuse to give consent.
- Previously enrolled patients in the present study.
- Hospitalization in the past two weeks.
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
June 1 2004
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT00130013
Start Date
September 1 2003
End Date
June 1 2004
Last Update
September 23 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ARI Research Cell, Children Hospital, Pakistan Institute of Medical Sciences
Islamabad, Capital, Pakistan, 44000